0000939767-18-000071.txt : 20180504 0000939767-18-000071.hdr.sgml : 20180504 20180504190652 ACCESSION NUMBER: 0000939767-18-000071 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180503 FILED AS OF DATE: 20180504 DATE AS OF CHANGE: 20180504 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schwab Gisela CENTRAL INDEX KEY: 0001213140 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30235 FILM NUMBER: 18809420 MAIL ADDRESS: STREET 1: 6701 KAISER DRIVE CITY: FREMONT STATE: CA ZIP: 94555 FORMER NAME: FORMER CONFORMED NAME: SCHWAB GISELA MD DATE OF NAME CHANGE: 20030107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC. CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 0102 BUSINESS ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508377000 MAIL ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS INC DATE OF NAME CHANGE: 20000207 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 4 1 wf-form4_152547516260192.xml FORM 4 X0306 4 2018-05-03 0 0000939767 EXELIXIS, INC. EXEL 0001213140 Schwab Gisela C/O EXELIXIS, INC. 210 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Pres Prod Dev & Med Aff & CMO Common Stock 2018-05-03 4 M 0 22500 5.50 A 300788 D Common Stock 2018-05-03 4 S 0 7800 22.36 D 292988 D Common Stock 2018-05-03 4 S 0 14700 23.47 D 278288 D Common Stock 14505 I By 401(k) Option (right to buy) 5.5 2018-05-03 4 M 0 22500 0 D 2012-09-28 2018-09-27 Common Stock 22500.0 90000 D Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,008 shares of common stock acquired on April 30, 2018, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.95 to $22.90. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.98 to $23.75. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 2, 2018. The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015. /s/ Jennifer Drimmer Rokovich, Attorney in Fact 2018-05-04